Further Analyses of GALACTIC-HF Supplement Previously Announced Data Regarding Increased Treatment Effect of Omecamtiv Mecarbil in Patients with More Severe Heart Failure SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented at […]
Other News
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology
Westport, CT, June 30, 2021 (GLOBE NEWSWIRE) — The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative […]
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the pricing of its upsized initial public offering of 8,682,142 shares of common stock at a […]
Vector to Debut Remote Cardiac Program Maturity Assessment at Heart Rhythm 2021
Constructive Feedback Helps Cardiology Practices Understand How to Improve their Remote Monitoring Programs BEND, Ore.–(BUSINESS WIRE)–Vector Remote Care announced today the launch of a Remote Cardiac Monitoring (RCM) Maturity Assessment to help cardiology practices understand both the current state of their program and how to grow and improve it to drive value […]
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
– KARDIA-1 will Evaluate Efficacy and Safety of Quarterly and Biannual Regimens of Zilebesiran as Monotherapy – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile-BEE-siran” and formerly known […]
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia. Javier San Martin, M.D., chief medical officer at […]
Ra Medical Systems Announces Progress with Guidewire-Compatible Catheter Design and Provides Update on Atherectomy Trial Enrollment
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces progress with finalizing the next-generation guidewire-compatible DABRA catheter design following a recent two-day, hands-on workshop with interventionalists who evaluated prototypes of the next-generation excimer […]
CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer
MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer. Mr. Ogilvie’s career spans decades in the medical technology sector and includes leadership roles in sales and marketing and corporate development, […]
Presidio Medical Announces Appointment of New Chief Executive Officer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Presidio Medical, Inc., a clinical-stage medical device company developing a transformational neuromodulation platform, today announced that Michael Onuscheck has been named the incoming Chief Executive Officer and Chairman of the Board. Mr. Onuscheck will be stepping down from his roles at Alcon, where he served as […]
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed’s (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. Impella RP with SmartAssist is the first single-access temporary percutaneous ventricular […]


